Table 3.
Cross sectional associations between FLD status and fibrosis among study participants with chronic HBV.
| Fibrosis Score (0-6) | Advanced Fibrosis (Ishak≥3) | ||||
|---|---|---|---|---|---|
|
| |||||
| n | Adjusted Mean Ratioa (95%CI) N=348 |
P-value | Adjusted RR (95%CI) N=348 |
P-value | |
| FLD status (ref=neither) | 289 | <0.001 | 0.002 | ||
| Steatosis | 77 | 0.89 (0.77, 1.03) | 0.58 (0.33, 1.02) | ||
| Steatohepatitis | 55 | 1.33 (1.15, 1.54) | 1.68 (1.12, 2.51) | ||
| Age, per 10 years | 421 | 1.07 (1.01, 1.13) | 0.01 | 1.21 (1.05, 1.39) | 0.01 |
| Sex (ref=Female) | 158 | 0.04 | 0.07 | ||
| Male | 263 | 1.13 (1.01, 1.27) | 1.44 (0.97, 2.13) | ||
| HBV DNA, per log10 IU/mL | 375 | 1.06 (1.02, 1.09) | 0.002 | 1.16 (1.04, 1.28) | 0.005 |
| ALT, per log2 U/mL | 350 | 1.16 (1.09, 1.22) | <0.001 | 1.24 (1.08, 1.43) | 0.003 |
Abbreviations: ALT, Alanine aminotransferase; FLD, fatty liver disease.
a
Since the Ishak fibrosis score was skewed to the right, a generalized linear model with the gamma link function was employed. Thus, mean ratios are reported. A mean ratio of 1.33 for steatohepatitis versus no FLD indicates that someone with steatohepatitis has, on average, 1.33 times higher Ishak fibrosis score compared to someone without FLD.